Greater Cannabis Company (GCAN) Receivables - Net (2020 - 2021)

Greater Cannabis Company's (GCAN) quarterly Receivables - Net came in at $36750.0 in Q3 2021, up 55.89% year-on-year from $23575.0 in Q3 2020, and little changed quarter-over-quarter from $36750.0 in Q2 2021.

Greater Cannabis Company (GCAN) Receivables - Net (2020 - 2021) Analysis & Trends

Greater Cannabis Company's Receivables - Net history runs 2 years deep, the most recent figure standing at $36750.0 for Q3 2021.

  • On a quarterly basis, Receivables - Net rose 55.89% year-over-year to $36750.0 in Q3 2021; TTM through Sep 2021 was $36750.0, a 55.89% increase from a year earlier, with the FY2020 full-year figure at $36750.0, changed N/A from the prior year.
  • Receivables - Net steadied at $36750.0 in Q3 2021 per GCAN's latest filing, from $36750.0 in the prior quarter.
  • Across five years, Receivables - Net topped out at $36750.0 in Q4 2020 and bottomed at $23575.0 in Q2 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Greater Cannabis Company 292,929.85 292,929.85 -

Historic Data

Download Data
DateValue
Sep 30, 2021 36,750.00
Sep 30, 2021 36,750.00
Jun 30, 2021 36,750.00
Jun 30, 2021 36,750.00
Mar 31, 2021 36,750.00
Mar 31, 2021 36,750.00
Dec 31, 2020 36,750.00
Dec 31, 2020 36,750.00
Sep 30, 2020 23,575.00
Sep 30, 2020 23,575.00
Jun 30, 2020 23,575.00
Jun 30, 2020 23,575.00